RxDoctor Payments Data

Jan Rodriguez Ferrer, MD

Internal Medicine · San Juan, PRNPI 1407969215

Payments from drug & device makers

$1,853in general payments, 2019–2025

Across 24 payments — averaging $77.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Merck$209
  • E.r. Squibb & Sons, L.L.C.$175
  • AstraZeneca$119
  • Pfizer$69
  • PBG Puerto Rico LLC$28
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson15$1,236
Merck3$209
E.r. Squibb & Sons, L.L.C.2$175
AstraZeneca1$119
Pfizer1$69
PBG Puerto Rico LLC1$28
Chiesi USA, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,853 in reported general payments places this provider in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$127,956
Medicare patients
76
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$20,316
XareltoRivaroxaban41$17,875
JanuviaSitagliptin Phosphate14$7,693
Xigduo XrDapaglifloz Propaned/Metformin13$6,253
SynthroidLevothyroxine Sodium42$2,298
Galantamine ErGalantamine Hbr33$2,160
Atorvastatin Calcium249$2,088
Memantine Hcl116$2,049
Levothyroxine Sodium140$1,616
SsdSilver Sulfadiazine32$1,510
Silver Sulfadiazine32$1,476
Levetiracetam65$1,367
Losartan Potassium134$1,178
LantusInsulin Glargine,hum.Rec.Anlog16$1,146
Metoprolol Succinate77$1,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$20,31638 claims
Johnson & JohnsonXarelto$1,236$17,87541 claims
MerckJanuvia$209$7,69314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →